<DOC>
	<DOCNO>NCT01665677</DOCNO>
	<brief_summary>Hematopoietic stem cell transplantation procedure person receive blood form stem cell person call `` donor '' . The stem cell obtain hollow part hip bone blood . A serious problem treatment Graft Versus Host Disease ( GVHD ) . This happen stem cell donor attack normal cell recipient . Currently , universal standard care United STates prevent GVHD . This study do see medicine use low cholesterol also help reduce GVHD . Patients receive atorvastatin daily mouth start 14 day stem cell transplant . They continue take atorvastatin 180 day transplant . This medicine may stop early bad side effect severe GVHD . Patients also receive standard treatment prevent GVHD . Patients undergo many test standard treatment West Virginia University ( WVU ) , include blood test check blood count , kidney function HIV status ; blood test check pregnancy ; Multi Gated Acquisition Scan ( MUGA scan ) echocardiogram test heart function ; lung function testing ; bone marrow aspirate biopsy . Patients also option provide blood sample optional research relate study .</brief_summary>
	<brief_title>Atorvastatin GVHD Prophylaxis Allogeneic Hematopoietic Cell Transplantation</brief_title>
	<detailed_description>Acute graft-versus-host disease ( GVHD ) one frequent complication allogeneic hematopoietic stem cell transplantation ( HSCT ) ( 1 ) . It develop 30-75 % recipient allogeneic HSCT depend degree histocompatibility donor recipient , number T-cells graft , recipient 's age GVHD prophylactic regimen use ( 2-4 ) . Novel strategy design effectively prevent development life threaten complication allogeneic transplantation urgently need .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Patient Eligibility Criteria : Patients history hematological malignancy bone marrow failure syndrome suitable allogeneic stem cell transplantation opinion treat transplant physician . Patients aged 1875 year age eligible . Patients age &gt; 18 ≤ 50 year eligible myeloablative conditioning ( MAC ) , patient &gt; 50 year age , previous history autologous transplantation , high hematopoietic cell transplant comorbidity index ( HCTCI ) score ( &gt; 2 ) , baseline diagnosis hodgkin 's lymphoma , chronic lymphocytic leukemia follicular lymphoma suitable reduce intensity conditioning ( RIC ) transplantation ( however intensity condition regimen remain discretion treat physician ) . All patient must least one suitable human leukocyte antigen ( HLA ) match sibling unrelated donor accord transplant center 's guideline ( selection appropriate sibling donor ) . Patient must provide informed consent . Left ventricular ejection fraction ≥ 40 % . No uncontrolled arrhythmia uncontrolled New York Heart Association class IIIIV heart failure . Bilirubin ≤ 2 x upper limit normal ( ULN ) aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) ≤ 3 x ULN ; absence hepatic cirrhosis . For patient Gilbert 's syndrome , bilirubin ≤ 3 x ULN permit . Adequate renal function define serum creatinine clearance ≥ 40 % normal calculate CockcroftGault equation . DLCOcor ( carbon monoxide diffuse capacity ; correct hemoglobin ) force expiratory volume one second ( FEV1 ) DL/VA ≥ 40 % predict ( pulmonary function test ) . Karnofsky performance status &gt; 70 . A negative pregnancy test require woman child bear potential . Breast feeding permit . Patients positive HIV serology eligible . No evidence active bacterial , viral fungal infection time transplant conditioning . Patients history intolerance allergic reaction atorvastatin eligible . Patients previously take atorvastatin statin drug eligible long contraindication switch atorvastatin ( 40mg/day ) opinion treat physician . Patients undergo Tcell deplete allogeneic transplantation eligible . Patients receive condition regimen contain antithymocyte globulin , and/or campath eligible . Method stemcell collection sibling donor discretion treat physician . Although anticipated majority sibling donor undergo Granulocyte colonystimulating factor ( GCSF ) induce stem cell mobilization ; however donor undergo bone marrow harvest stem cell mobilization experimental agent ( e.g . plerixafor ) remain eligible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Graft v Host Disease</keyword>
	<keyword>GVHD</keyword>
	<keyword>Allogeneic hematopoietic stem cell transplantation</keyword>
	<keyword>HSCT</keyword>
	<keyword>Atorvastatin</keyword>
</DOC>